^
Association details:
Biomarker:PD-L1 expression
Cancer:Lung Adenocarcinoma
Drug Class:Immunotherapy +
Angiogenesis inhibitor
Direction:Sensitive
Evidence:
Evidence Level:
Sensitive: C3 – Early Trials
Title:

Efficacy and safety of combined immunotherapy and antiangiogenic therapy for advanced non-small cell lung cancer: a real-world observation study

Published date:
05/19/2023
Excerpt:
Of the 85 NSCLC patients with ICIs combined antiangiogenic therapy, 28 achieved PR, 43 achieved SD, and 14 achieved PR. The ORR was 32.9%, and the DCR was 83.5% (Table 5). PD-LI expression was associated with treatment responses in advanced NSCLC patients (p = 0.000), both in adenocarcinoma (p = 0.007) and squamous cell carcinoma (p = 0.049).
DOI:
https://doi.org/10.1186/s12890-023-02470-z